GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of the co-agonism question that gets asked weekly, answered properly — 50 comments in the full submission. View in context.
1k
c/cagrilintide·submitted 4 months ago by u/bpc_sceptic

the co-agonism question that gets asked weekly, answered properly

Cautionbranch of 9 comments

Long-ish post, sorry. tl;dr at the bottom. I have been tracking cagrilintide against eGFR for 15 weeks because I could not find anyone who had. The correlation is weaker than I expected, which is itself mildly interesting given how confidently people link the two in here. Caveats up front: one person, one lab, one…

Read the full submission and all 50 comments →

This branch

9 comments, started 4 months ago
u/kavya_kravchenko108 points·4 months ago

Rodent or human data?

replysharereportpermalink
u/amylin_amyMOD34 points·4 months ago

This is an urgent-care question wearing a forum question's clothes. Please contact a clinician rather than waiting for replies.

replysharereportpermalink
u/noor_ivaturi27 points·4 months ago

amylin receptor distribution is different from GLP-1

replysharereportpermalink
u/nadia_fonseca8 points·4 months ago

Small correction: the trial was 16 weeks, not 26. Does not change your point but people will quote it.

replysharereportpermalink
load more comments (1) →
u/lukas_vermeulen45 points·4 months ago

REDEFINE readouts are phase 8 data

replysharereportpermalink
u/hana_pereira11 points·4 months ago

long-acting amylin is co-agonism, different satiety profile

replysharereportpermalink
u/bpc_scepticOPresearch peptides-7 points·4 months ago

REDEFINE phase 3 readouts are interesting but 3 person satiety is different from 3 trial satiety.

replysharereportpermalink
u/ahmed_fonseca12 points·4 months ago

the mechanism is different, the side effect profile reflects it

replysharereportpermalink

← back to the whole thread

About c/cagrilintide

Amylin analog pharmacology and the CagriSema combination: why amylin and GLP-1 co-agonism produces a different satiety profile, the REDEFINE readouts, and the very limited pool of people handling cagrilintide as research material.

19kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/cagrilintide
c/cagrilintide rules
  1. Amylin is not a GLP-1. Posts conflating them get corrected.
  2. CagriSema ratios in trials are fixed-dose. Do not extrapolate to self-mixing.
  3. Not approved anywhere. Keep posts descriptive, not instructional.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/amylin_amyu/incretin_ivyu/ledger_mod
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →